FDA approves first twice-a-year HIV prevention shot with near-perfect effectiveness
The FDA has approved lenacapavir (Yeztugo), the first HIV prevention injection requiring just two doses a year. Clinical trials showed it prevented infection in over 99.9% of participants. Developed by Gilead Sciences, the drug targets HIV at multiple lifecycle stages. Royalty-free licensing deals aim to bring affordable versions to 120 countries. The World Health Organization has already recommended it as a new PrEP option, marking a significant shift in global HIV prevention strategy.









